0001104659-24-000584.txt : 20240103 0001104659-24-000584.hdr.sgml : 20240103 20240103081519 ACCESSION NUMBER: 0001104659-24-000584 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231229 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 24504404 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 N., SUITE 301 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 8-K 1 tm2333851d1_8k.htm FORM 8-K
false 0001566044 0001566044 2023-12-29 2023-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 29, 2023

 

VYNE Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38356   45-3757789

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

685 Route 202/206 N., Suite 301

Bridgewater, New Jersey 08807

(Address of principal executive offices, including Zip Code)

 

(800) 775-7936

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VYNE   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

As previously disclosed, in connection with VYNE Therapeutics Inc.’s (the “Company”) private placement financing on November 1, 2023, the Company agreed to appoint one designee of Access Industries, Inc. (“Access Bio”) to the Board of Directors (the “Board”) of the Company. On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024, for a term continuing to the Company’s 2026 annual meeting of stockholders and until her successor is appointed. The Board has determined that Dr. Borowski satisfies the definition of an “independent director” under the Nasdaq Stock Market listing standards and applicable U.S. Securities and Exchange Commission (“SEC”) rules.

 

Dr. Borowski, age 46, has served as Vice President at Access Bio since January 2022, and previously served as Senior Associate beginning in July 2019. Prior to that, Dr. Borowski worked on therapeutics company creation at Apple Tree Partners from 2017 to May 2019. Before joining Apple Tree Partners, Dr. Borowski worked as an editor at several high-impact scientific journals, most recently as Chief Editor of Nature Medicine from 2014 to 2017. She earned a B.S. in Biology at the University of Kentucky, a Ph.D. in Immunology at Harvard University, and completed her postdoctoral work on natural killer T cell development at the University of Chicago.

 

In connection with her appointment, pursuant to the Company’s non-employee director compensation policy, Dr. Borowski was granted an option to purchase 40,000 shares of the Company’s common stock with an exercise price equal to $2.33 per share. This option award will vest annually over three years on the anniversary of the date of grant, subject to her continued service to the Company through each vesting date. In addition, following each annual meeting of stockholders of the Company, Dr. Borowski will receive an option award to purchase an amount of shares equal to 0.046% of the total shares then outstanding (inclusive of pre-funded warrants), subject to her continued service to the Company through each grant date, consistent with other non-employee directors of the Company. In addition, Dr. Borowski will receive the standard annual cash retainer of $40,000, payable quarterly. Dr. Borowski has also entered into the Company’s standard form of indemnification agreement.

 

There are no related party transactions between Dr. Borowski and the Company that would require disclosure under Item 404(a) of Regulation S-K. There is no family relationship between Dr. Borowski and any of the Company’s other directors or executive officers.

 

Item 7.01 Regulation FD Disclosure.

 

On January 3, 2024, the Company issued a press release announcing Dr. Borowski’s appointment to the Board. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number		   Exhibit Description
99.1   Press Release dated January 3, 2024.
104   Cover Page Interactive Data File (formatted as inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VYNE THERAPEUTICS INC.
     
Date: January 3, 2024 By: /s/ Mutya Harsch
    Mutya Harsch
    Chief Legal Officer and General Counsel  

 

 

 

 EX-99.1 2 tm2333851d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

 

BRIDGEWATER, N.J., January 3, 2024 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024.

 

“We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company’s growth,” said David Domzalski, President and CEO of VYNE. “With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable perspectives as we seek to execute on our strategic objectives of developing novel immuno-inflammatory therapies through our InhiBET™ platform.”

 

Dr. Borowski has served as Vice President at Access Biotechnology, a leading healthcare investor, since January 2022, and previously served as Senior Associate beginning in July 2019. Prior to that, Dr. Borowski worked on therapeutics company creation at Apple Tree Partners. Before joining Apple Tree Partners, Dr. Borowski worked as an editor at several high-impact scientific journals, most recently as Chief Editor of Nature Medicine. She earned a B.S. in Biology at the University of Kentucky, a Ph.D. in Immunology at Harvard University, and completed her postdoctoral work on natural killer T cell development at the University of Chicago.

 

Dr. Borowski added, “This is such an exciting time for VYNE.  I look forward to working with the team as they develop their pipeline of unique BET inhibitors as a promising new drug class for treating serious inflammatory disorders.”

 

About VYNE Therapeutics Inc.

 

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited.

 

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the future expectations, plans and prospects of VYNE, the execution of its strategic objectives and contributions of Dr. Borowski. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results in, clinical trials for its product candidates; and VYNE’s future financial performance and liquidity. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2022, VYNE’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

 

Investor Relations:

 

John Fraunces

LifeSci Advisors, LLC

917-355-2395

jfraunces@lifesciadvisors.com

 

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com

 

 

 

 EX-101.SCH 3 vyne-20231229.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vyne-20231229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 vyne-20231229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2333851d1_ex99-1img001.jpg GRAPHIC begin 644 tm2333851d1_ex99-1img001.jpg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�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htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 29, 2023
Entity File Number 001-38356
Entity Registrant Name VYNE Therapeutics Inc.
Entity Central Index Key 0001566044
Entity Tax Identification Number 45-3757789
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 685 Route 202/206 N.
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Bridgewater,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 800
Local Phone Number 775-7936
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol VYNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2333851d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001566044 2023-12-29 2023-12-29 iso4217:USD shares iso4217:USD shares false 0001566044 8-K 2023-12-29 VYNE Therapeutics Inc. DE 001-38356 45-3757789 685 Route 202/206 N. Suite 301 Bridgewater, NJ 08807 800 775-7936 false false false false Common Stock, $0.0001 par value VYNE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://menlotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2333851d1_8k.htm vyne-20231229.xsd vyne-20231229_lab.xml vyne-20231229_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333851d1_8k.htm": { "nsprefix": "vyne", "nsuri": "http://menlotherapeutics.com/20231229", "dts": { "inline": { "local": [ "tm2333851d1_8k.htm" ] }, "schema": { "local": [ "vyne-20231229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "vyne-20231229_lab.xml" ] }, "presentationLink": { "local": [ "vyne-20231229_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://menlotherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333851d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333851d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-000584-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-000584-xbrl.zip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end